High frequency chest wall oscillation for airway clearance in bronchiectasis.
Imad BouAkl, Jana Bazzi, Antonio Esquinas and 1 others
Across the available trials, HFCWO outperformed chest physiotherapy on breathlessness and lung function in one small RCT, but showed no difference in hospital stay in another.
Observational data suggest fewer hospitalizations, but cannot establish causation.
Key findings
1In a 30-patient RCT, HFCWO produced greater improvements in breathlessness (BCSS) and quality-of-life (CAT) scores than conventional chest physiotherapy (p ≤ 0.001 for both), and showed significant increases in FVC and FEV1.
2In a 280-patient RCT comparing conventional chest physiotherapy with HFCWO, hospital length of stay was not significantly different (12.5 ± 8.8 days vs. 13.0 ± 8.9 days, p = 0.62).
3Multiple retrospective before-and-after studies report significant reductions in hospitalizations (e.g., 49.1% to 24% of patients; 0.887 to 0.404 admissions per patient per year) and a 67% reduction in bronchiectasis-related hospitalizations after HFCWO initiation, but these designs cannot separate the device effect from concurrent treatments or natural disease course.
Still to come
How it was doneWhat they foundWhat it means for PTs
Read the rest of this summary
You get three full summaries a month, free, and we do not ask for a card. Search, the TL;DRs and your library stay unlimited either way.
What it does not show
The two RCTs are small (30 and 280 patients) and short (15 days); the 280-patient trial was underpowered for its primary outcome and the bronchiectasis subgroup (n = 71) showed no significant differences. All observational and registry studies are retrospective before-and-after designs with no control group, so improvements cannot be attributed to HFCWO alone when patients were also receiving bronchodilators, mucolytics, and macrolide therapy. The review is narrative, not a systematic review with formal quality appraisal or meta-analysis, so the weight of evidence is uneven and difficult to appraise. Heterogeneous populations (CF and non-CF bronchiectasis, mixed diagnoses in the Clinkscale trial) limit generalisability. No standardised HFCWO protocol exists across studies; frequency, pressure, session duration, and number of sessions varied. Long-term adherence is a known problem: bulky equipment, noise, and time commitment reduce compliance, especially in milder disease.
Declared interests
The authors declared that no financial support was received for the work or its publication.
The easy way to misread this
Do not read the 50–67% reductions in hospitalizations as proof that HFCWO causes them. These figures come from before-and-after comparisons in patients who were simultaneously receiving nebulised bronchodilators, mucolytics, and macrolide therapy, with no control group. The only head-to-head RCT with a bronchiectasis-specific primary outcome (Clinkscale, 280 patients) found no significant difference in hospital stay between HFCWO and conventional chest physiotherapy (p = 0.62).
Summarised by AI from the full paper, without a clinician reviewing it. Check it against the source before it changes what you do. Read it on PubMed →